- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (26)
Query did not match any clinical trials.
| These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006). | |
| Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records. | |
| Study title: A Postlicensing Study to Determine Long-Term Safety of Alphanate® in Previously-Treated Patients Diagnosed with Severe Hemophilia A |
| Active substance: HUMAN COAGULATION FACTOR VII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29144 |
| Study title: Clinical Study of Recovery and Half-Life of Factor VII Concentrate (Human Immuno 1988-1991) |
| Active substance: HUMAN COAGULATION FACTOR VII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29142 |
| Study title: Compassionate Use of Factor VII, VH |
| Active substance: HUMAN COAGULATION FACTOR VII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29141 |
| Study title: Low risk if viral infection after administration of vapor heated factor VII concentrate or factor IX complex in first time recipients of blood components |
| Active substance: HUMAN COAGULATION FACTOR VII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29140 |
| Study title: Open-Label Clinical Study of Long-Term Treatment and Prophylaxis with Factor VII Concentrate (Human) Immuno, Vapor Heated" |
| Active substance: HUMAN COAGULATION FACTOR VII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29138 |
| Study title: Single Patient Use of Factor VII Concentrate |
| Active substance: HUMAN COAGULATION FACTOR VII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29143 |
| Study title: Study to determine the safety of virus inactivated factor concentrates in hemophiliacs naive to blood product administration (IFSS) |
| Active substance: HUMAN COAGULATION FACTOR VII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29139 |
| Study title: A study on the safety and efficacy of FEIBA VH Immuno in Hemophilia Patients with Inhibitors Hemophiliac Treatment Research Study |
| Active substance: HUMAN COAGULATION FACTOR VIII |
| Study summary document link (including results): 05 ATG95-03 (full).pdf |
| View full study record |
| Document reference: 29148 |
| Study title: Clinical study to investigate the efficacy, safety and immunogenicity of Wilate in children < 6 years of age with inherited von willebrand disease. |
| Active substance: HUMAN COAGULATION FACTOR VIII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29157 |
| Study title: Efficacy and safety in children with severe Haemophilia A treated with OCTANATE (Phase III) |
| Active substance: HUMAN COAGULATION FACTOR VIII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29156 |
| Study title: Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery or invasive procedures in subjects with congenital von Willebrand disease |
| Active substance: HUMAN COAGULATION FACTOR VIII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29146 |
| Study title: Efficacy Study of FEIBA IMMUNO Vapor Heated Versus Factor IX Complex (Human) IMMUNO, Vapor Heated, in the Management of Patients with Hemophilia A with Inhibitors |
| Active substance: HUMAN COAGULATION FACTOR VIII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29150 |
| Study title: Evaluation of the Pharmacokinetic, Clinical Efficacyand Safety of the Concentrate of Factor VIII, Emoclot D.I., in patients affected by Haemophilia A |
| Active substance: HUMAN COAGULATION FACTOR VIII |
| Study summary document link (including results): 06 IG95-01B (full).pdf |
| View full study record |
| Document reference: 29154 |
| Study title: Familiarization Phase of FEIBA Immuno Study (Hilgartner) |
| Active substance: HUMAN COAGULATION FACTOR VIII |
| Study summary document link (including results): 03 IG405 (synopsis).pdf |
| View full study record |
| Document reference: 29149 |
| Study title: Human Plasma derived Antihemophilic Factor VIII: Evaluation of Efficacy, Tolerability and Safety in Previously Treated Severe Hemophilia A Patients. An Open non-Comparative Phase III Study. |
| Active substance: HUMAN COAGULATION FACTOR VIII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29153 |
| Study title: IG 95-01B: Retrospective pharmacovilance study. Safety study on the double-inactivated human antihaemophilic factor concentrate (Fanhdi) Grifols, during prophylaxis and/or treatment of patients with haemophilia A. |
| Active substance: HUMAN COAGULATION FACTOR VIII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29151 |
| Study title: Incidence of inhibitors in previously untreated patients with severe haemophilia A treated with Octanate |
| Active substance: HUMAN COAGULATION FACTOR VIII |
| Study summary document link (including results): 04 UK95-02 (full).pdf |
| View full study record |
| Document reference: 29155 |
| Study title: Post Marketing Pharmacovigilance Study (ATC 9503) with Profilate (SD, HT) |
| Active substance: HUMAN COAGULATION FACTOR VIII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29145 |
| Study title: Report UK 95-02: Retrospective review of inhibitor formation in a cohort of haemophilia A patients who received Alphanate (Alpha 8 ST) prophylactically |
| Active substance: HUMAN COAGULATION FACTOR VIII |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29152 |
| Study title: |
| Active substance: HUMAN COAGULATION FACTOR VIII AND HUMAN VON WILLEBRAND FACTOR |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29159 |
